Peptide Therapeutics Market Expected to Witness Significant Growth

Strategic Insights -

The peptide therapeutics market is expected to register a CAGR of 9.66% over the forecast period due to the increasing prevalence of cancer and metabolic disorders, rising investments in research and development of novel drugs, and technological advancements. The market is driven by the high specificity, discernment, small sizes, ease of modification, and high biocompatibility of peptide therapeutics.

Key Takeaways:

  • The market growth is driven by the increasing prevalence of cancer and metabolic disorders, rising investments in research and development of novel drugs, and technological advancements in peptide therapeutics.
  • Cancer cases are expected to increase by 56.7% by 2040, making peptide therapeutics a crucial component in cancer treatment and diagnosis.
  • Peptide therapeutics have shown significant results in cancer treatment, with new-generation peptide therapeutics targeting cancer-specific signatures.
  • The rising prevalence of metabolic disorders, such as Gaucher disease, is fueling the demand for peptide therapeutics for treating metabolic disorders.
  • Technological developments, such as the expansion of the strategic collaboration between BioNTech SE and Regeneron, are fueling the market's growth.
  • North America is expected to dominate the market due to increased awareness levels relating to peptide therapeutic products, the increasing necessity for diagnostics in cancer and other diseases, and the developing biotechnology industry.
  • The cancer segment is expected to witness significant growth due to the increasing frequency of cancer globally and increasing prescription of peptide therapeutics for cancer treatment.

Statistics:

  • The peptide therapeutics market is expected to register a CAGR of 9.66% over the forecast period.
  • Cancer cases are expected to increase by 56.7% by 2040.
  • 1.9 million new cancer cases are expected to be diagnosed in the US in 2022.
  • The prevalence of Gaucher disease is estimated to be 1.5 cases per 100,000 live births and 0.9 cases per 100,000 inhabitants globally.
  • $2.8 million grant was awarded to ElicioTherapeutics to fund research for two therapeutic cancer vaccines.

Sources:

  • "Global Cancer Statistics 2020" by Globocan
  • "Cancer Facts & Figures 2022" by the American Cancer Society
  • "JPHO" (July 2022)
  • "SCB" (February 2021)
  • "BioNTech SE" (March 2022)
  • "Gastro-Intestinal Research Foundation" (September 2022)
  • "IDF" (December 2021)